Clene Inc. has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for CNM-Au8, a treatment for amyotrophic lateral sclerosis (ALS). The application is based on biomarker data and clinical outcomes indicating potential benefits. Clene aims to advance CNM-Au8 through regulatory review while preparing for a confirmatory Phase 3 study. This development offers hope for new treatment options for ALS patients, targeting neuronal health and survival.
Clene's submission of a New Drug Application for CNM-Au8 in ALS treatment is presented here with Pluang's Health-sector market data as of Oct 19, 2026 18:01 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 73 rose and 47 fell today. Moderna (MRNA) traded at USD 213.00 with a 1-day decline of 2.30% and a typical hold time of 59 days, contrasting with Revolution Medicines (RVMD) at USD 181.96 gaining 2.25% and held typically for 4 days, while Tango Therapeutics (TNGX) rose 2.00% to USD 22.48 with a similar short hold time of 4 days.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
